Anticoagulation and Antiplatelet Agents

A Panel Discussion among Two Hematologists, Five Cardiologists, and Two Interventional Cardiologists

December 2008

Deliverable: Transcript with key findings 

Study Description and Objectives

§    Review recent data from the ATLAS trial presented at AHA 2008 and compare it to data on Schering Plough’s SCH 530348, Bristol-Myers Squibb and Pfizer’s apixaban, and Eisai’s E5555

§    Assess the strengths/weaknesses of and expectations for the following medications in the treatment of atrial fibrillation and DVT prevention following orthopedic surgery:

·     Bayer’s Xarelto® (rivaroxaban; Factor Xa inhibitor)

·     Portola’s betrixaban (Factor Xa inhibitor)

·     Schering Plough’s SCH 530348 (thrombin receptor antagonist)

·     Eisai’s E5555 (thrombin receptor antagonist)

·     Bristol-Myers Squibb and Pfizer’s apixaban (Factor Xa inhibitor)

·     Boehringer-Ingelheim’s dabigatran (a direct thrombin inhibitor)

§    Discuss the potential for dabigatran’s approval for atrial fibrillation and how it might impact the use  of Factor Xa inhibitors in this space

§    Determine the important of being first-to-market in the treatment of acute coronary syndrome and atrial fibrillation and evaluate the factors involved in changing patients to a new therapy once it is approved

Companies and Products Mentioned in this Report

Inclusion Criteria and Panel Details

Inclusion Criteria

§    US-based §    Training and board-certified in specialty §    2 - 30 years of experience post-training §    Physicians with significant clinical trial experience (does not need to be academic) §    Physicians familiar with anticoagulants and antiplatelet agents ·     Bayer’s Xarelto® (rivaroxaban; Factor Xa inhibitor) ·     Bristol-Myers Squibb and Pfizer’s apixaban (Factor Xa inhibitor) ·     Boehringer-Ingelheim’s dabigatran (a direct thrombin inhibitor) ·     Portola’s betrixaban (Factor Xa inhibitor) ·     Schering Plough’s SCH 530348 (thrombin receptor antagonist) ·     Eisai’s E5555 (thrombin receptor antagonist) §    Physicians familiar with the anticoagulant and antiplatelet trials ·     RECORD ·     ATLAS ·     APPRAISE ·     ADVANCE ·     TRA-PCI ·     EXPERT

Discussion Dates

November 26, 2008 through December 16, 2008

Panelists' Institutions:

Institution	State
Brigham and Women's Hospital	MA
Duke Medical Center	NC
Duke University Medical Center	NC
Montefiore Medical Center, Albert Einstein College of Medicine	NY
North Shore University Hospital at Manhasset	NY
Orlando Heart Center	FL
Private Practice	CA
University of Washington	WA
Western Pennsylvania Hospital	PA

Print Abstract

For additional information on this study or to purchase, please call: